We would like to thank Pascal DuBois for proof-reading the article. The authors would also like to thank the personnel of the Animal Facility at Hunter College of The City University of New York. This work was supported by a NIH RCMI grant to Hunter College.

Etik Beyanı Tüm hayvan çalışmaları New York Şehir Üniversitesi Hunter College Kurumsal Hayvan Bakım ve Kullanım Komitesi (IACUC) tarafından onaylanmıştır. Not: Sekiz BALB / c fareleri, bu deneysel prosedür kullanılmıştır. Beş BALB / c fareleri, primer tümör üretmek için 5 x 10 6 BNL 1ME A.7R.1 fare hepatoselüler karsinoma hücreleri ile implante edildi. Herhangi bir nakil Üç BALB / c fareleri, kontroller olarak kullanılmıştır. BNL 1ME A.7R.1 sıçangil olmayan tümörijenik hepatosit hücre çizgisi BNL CL.2 kimyasal dönüştürme ile elde edilen bir murin hepatosellüler karsinom hücre hattıdır. BNL 1ME A.7R.1 Amerikan Tip Kültür Koleksiyonu (ATCC) elde edilmiştir. 1. Ön cerrahi <ol><li> Tüm yaşam ameliyatları sağlıklı için fareler olun. Fareler sağlıklı olduğundan emin olmak için, cilt tenting ile dehidratasyon belirtileri kontrol edin. Hastalık ya da d herhangi bir kanıt ile fareler kullanmayınBu deneylerde istress. </li><li> Onlar kilolu olmayan sağlamak için farelerin tartılır. Ağırlığı en az 16-20 gram olduğundan emin olun. </li><li> Fare başına implantasyon için 5 x 10 6 BNL 1ME A.7R.1 fare HCC hücreleri hazırla: <ol><li> BNL 1ME A.7R.1 fare HCC hücrelerinin% 70 birleşen hücre kültürü çanak - 10 ml&#39;lik% 60 aspire medya. 5 ml PBS ile iki kez yıkanır. Çanak tripsin 2 ml ilave edilir ve 5 dakika boyunca hava ve% 5 CO2 ile nemlendirilmiş bir kuluçka makinesi içinde 37 ° C&#39;de inkübe edin. </li><li> Daha sonra, bir pipet 10 ul 10X büyütmede mikroskop altında hücre sayımı için manuel bir hemasitometre içine hücreleri tripsinize. Dört büyük köşe meydanlarda bulunan hücrelerin toplam sayısını ve toplam hücre sayısına göre seyreltme faktörünü çarpın. Ardından, (ml başına hücreleri) sayılan kareler sayısına göre bölmek ve hücre konsantrasyonu 10 6 ile çarpın. </li><li> Hesaplama kullanarak, steril fare başına 5 milyon hücreleri toplamak1.5 ml mikrosantrifüj tüpleri. 1.5 ml mikrosantrifüj tüpler etiketleyin. </li></ol></li><li> Fosfat tamponlu tuzlu su, 100 ul (PBS) içinde 5 x 10 6 BNL 1ME A.7R.1 fare HCC hücrelerinin yeniden süspanse edin. Cerrahi implantasyon kadar buz üzerinde bu hücreleri tutun. </li><li> Böyle anestezi indüksiyon ve saç kirlenmesini önlemek için steril ekipman ve materyallerden uzak kırpma olarak ameliyata farelerin hazırlanması için gerekli aktiviteleri yapın. </li><li> Ve dakika başına 1 L (yakl.% 2.1) sabit bir konsantrasyonu, bir akış oranında oksijenle birlikte izofluran buharlaştırıcı kullanılarak izofluran teneffüs ettirilerek farelerde, genel anestezi neden. Not: Sistem kendi kendine yeten ve hassas bir buharlaştırıcı, bir oksijen kaynağı ve gaz / anestezik atma için gerekli bir solunum devresine bağlı olan bir aktif karbon filtresi içerir. </li><li> Anestezi, ameliyat sırasında ağrı geçiyor gelen hayvan önlemek için yeterli olduğundan emin olun. Ayak-tutam gerçekleştirin ve non-sorumluluk gibi için hayvan gözlemlemekcilik anestezi onaylayın. </li><li> O zaman, burun konisi vana hattı, mühür kutusuna açık geçiş yapın. </li><li> En kısa sürede fare anestezi olarak, kurutma ve hasardan koruyucu bir önlem olarak kornealara bir göz merhemi küçük bir miktar uygulayın. </li><li> Daha sonra, burun konisi düzgün (bakım anestezi için) yerleştirilir ve bağlı olan, hazırlık alanı hayvan taşımak. Bu hazırlık alanında Depilasyon tarafından ameliyat için cerrahi kesi yeri hazırlayın. </li><li> Cerrahi alan diğer tüm aktivite ücretsiz bir yerde olduğundan emin olun. </li><li> Çalışma yüzeyi sağlam ve uygun dezenfekte, unsoiled ve dağınıklıktan arınmış ameliyattan önce olduğundan emin olun. Keten ya da üzerinde cerrahi tepsi steril parça yerleştirin. </li><li> Operatif alan ameliyatı yapan yalnızca kişilerin mevcut olduğundan emin olun. Cerrahi oda uygun bir dezenfeksiyon ile temizlenmeli ve uygun bir temizleyici ile süpürüldü ve püskürtülür emin olunctant. </li><li> O da uzak kapılar ve hava akımlarından olarak windows konumlandırılmış sitenin kirlenme giden toz yayılabilir emin olun. </li><li> Steril aletler ile hayatta kalma ameliyat gerçekleştirin. Ya üreticinin tavsiyesine veya otoklav göre dezenfektan aletleri ıslatın. Kullanıma hazır olan temel steril malzemeleri kullanın. </li><li> Ayrı araçlar işlevlerine göre steril alanlara bulaşmasını önlemeye yardımcı olur. </li><li> Hayvanın karaciğeri erişmek için kesi (orta hat insizyonu) sitesinde etrafında yaklaşık 1 inç tıraş. Ameliyat bölgesinde uzak hayvandan saç çıkarın. </li><li> Tıraştan sonra sabunlu dezenfektan (betadin cerrahi fırçalayın) alanı fırçalayın ve steril PBS solüsyonu ile aşırı dezenfektan silsin. Yaklaşık 5 dakika süren tüm bodur süreci ile, bu birkaç kez yapın. Çıkarın ve kullanılan eldivenler atılır. </li><li> Daha sonra, bu tür Surgic olarak koruyucu giysi değiştirmekal elbisesi, bodur üst ve yüz maskesi. Sonraki cerrahi eldiven takmadan önce doğru fırçalayın solüsyonu ile eller dezenfekte. Not: Bu dökülme ve potansiyel kirleticiler ile cerrahi siteyi kirlenmesine önlemek için gerekli bir adımdır. </li></ol> 2. Cerrahi <ol><li> Anestezi tüm süre boyunca sıcaklık için bir dış ısı kaynağı sağlar. Anestezi termoregülasyonun bozuklukları neden olduğundan hayvan bazı hipotermi karşılaşabilirsiniz; Bu nedenle, vücut ısısını muhafaza. </li><li> Ameliyat boyunca sırtında fare yerleştirin. </li><li> Cerrahi bantlar parçaları ile ameliyat masasına ön bacaklarda, arka bacaklarda ve fare kuyruğu sabitleyin. </li><li> Xyphisternum düz bir çizgi kesi hemen aşağı olun. </li><li> Karaciğeri maruz steril kendini istinat cerrahi retraktörü kullanın. </li><li> Bir şırınga yavaş ve dikkatli bir 20G iğne sahip olan 5 x 10 6 BNL 1ME A.7R.1 içeren PBS 100 ul enjekteKaraciğerin sağ lobunun içine fare HCC hücreleri. </li><li> İğneyi çıkardıktan sonra, bağlı karaciğer yüksek vaskülarite için herhangi bir potansiyel kanamayı durdurmak için en az 1 dakika süreyle steril bir pamuklu çubuk uygulayın. </li><li> Cerrahi klipleri kullanarak cilt kapatılması ve ardından bir emilebilir sütür ile cilt altı dokusu kapatın. Daha sonra, betadin fırçalayın ile bir kez daha yara temizleyin. Not: Bu cerrahi yaranın kapanmasını sağlayacaktır. </li><li> Subkutan serum fizyolojik 100 ul verir. </li></ol> 3. Post-cerrahi <ol><li> Ameliyattan hemen sonra, fare durumun bakıcıları bildirmek için bir ameliyat sonrası kimlik kartı ile temiz bir kafes fare aktarın. Su ve yiyecek sağlamak. Not: Bizim tecrübelerimize göre, ilk 24 saatlik süre sonrası ameliyat için ıslak yiyecek ve su ile tek başına ev sahipliği eğer sadece en iyi ücret olacak ameliyat geçirmiş bir fare. </li><li> 38 ºC aşarak değil ısı üreten bir ısı lambası ile hayvan sıcak tutun. UFare tamamen iyileşti kadar sıcaklığını ölçmek için bir termometre se. </li><li> Tercihen kağıt yatak ile bir kafes içinde Evi hayvan konfor sağlamak için. </li><li> İlk kurtarma sonra, rahatsızlık, kanama, ağrı ve sıkıntı belirtileri için hayvan izleyin. Ağrı gidermek için buprenorfini (0.05 -0.1 mg / kg) verin. Yakından yaklaşık 2 saat boyunca aktivitesi, davranış ve görünüm, hem de su ve gıda tüketimi izler. Ayaktan ise, farelerin normal, normal konut için geri alan hayvan taşımak ve 24 saat sonrası ameliyat için 6-12 saat aralıklarla izlemeye devam. İsterseniz bir ağırlık kontrolü yapın. </li><li> Hayvan sorunları iyileşirken sahip Ancak, eğer uygun destekleyici bakım eylemleri. Fareler kurtarmak için yapamıyorsanız, insancıl CO 2 boğulma ve servikal dislokasyon yoluyla fareler euthanize. Ötenazi için onaylanan kurumsal yönergeleri izleyin. </li><li> Post-cerrahi, genellikle observab olan HCC klinik kanıt kontrolvücut kondisyon skoru le olarak anlamlı bir azalma. Not: Bu noktada, bir primer tümör olasılıkla karaciğerde gelişmiş ve metastatik yatakları olasılıkla akciğer gelişmiştir. </li><li> Bu noktada, insani ötenazi deneyde yer alan (deney ve kontrol) tüm fareler kurban. Karbon dioksit ile boğularak fareler Konu: çok yavaş 5 -10 dakikalık bir süre boyunca bölme içine karbon dioksitin bırakın. Bu solunum durmasına neden olur. </li></ol>

<ol>
	<li>Sheng, W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Capture,+release+and+culture+of+circulating+tumor+cells+from+pancreatic+cancer+patients+using+an+enhanced+mixing+chip.">Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip.</a> Lab on a Chip. 14, 89-98 (2014).</li><li>Ogunwobi, O. O., Liu, C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Therapeutic+and+prognostic+importance+of+epithelial-mesenchymal+transition+in+liver+cancers:+insights+from+experimental+models.">Therapeutic and prognostic importance of epithelial-mesenchymal transition in liver cancers: insights from experimental models.</a> Critical Reviews in Oncology/Hematology. 83, 319-328 (2012).</li><li>Ogunwobi, O. O., Puszyk, W., Dong, H. J., Liu, C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Epigenetic+upregulation+of+HGF+and+c-Met+drives+metastasis+in+hepatocellular+carcinoma.">Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma.</a> PloS One. 8, e63765 (2013).</li><li>Ogunwobi, O. O., Liu, C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Hepatocyte+growth+factor+upregulation+promotes+carcinogenesis+and+epithelial-mesenchymal+transition+in+hepatocellular+carcinoma+via+Akt+and+COX-2+pathways.">Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways.</a> Clinical and Experimental Metastasis. 28, 721-731 (2011).</li><li>Fujiwara, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+novel+animal+model+for+in+vivo+study+of+liver+cancer+metastasis.">A novel animal model for in vivo study of liver cancer metastasis.</a> World Journal of Gastroenterology : WJG. 18, 3875-3882 (2012).</li><li>Wirtz, D., Konstantopoulos, K., Searson, P. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+physics+of+cancer:+the+role+of+physical+interactions+and+mechanical+forces+in+metastasis.">The physics of cancer: the role of physical interactions and mechanical forces in metastasis.</a> Nature Reviews Cancer. 11, 512-522 (2011).</li><li>Heindryckx, F., Colle, I., Van Vlierberghe, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Experimental+mouse+models+for+hepatocellular+carcinoma+research.">Experimental mouse models for hepatocellular carcinoma research.</a> International Journal of Experimental Pathology. 90, 367-386 (2009).</li><li>Zhang, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=An+in+vivo+mouse+model+of+metastatic+human+thyroid+cancer.">An in vivo mouse model of metastatic human thyroid cancer.</a> Thyroid Official Journal of the American Thyroid Association. 24, 695-704 (2014).</li><li>Menezes, M. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Genetically+engineered+mice+as+experimental+tools+to+dissect+the+critical+events+in+breast+cancer.">Genetically engineered mice as experimental tools to dissect the critical events in breast cancer.</a> Advances in Cancer Research. 121, 331-382 (2014).</li><li>Ogunwobi, O. O., Wang, T., Zhang, L., Liu, C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cyclooxygenase-2+and+Akt+mediate+multiple+growth-factor-induced+epithelial-mesenchymal+transition+in+human+hepatocellular+carcinoma.">Cyclooxygenase-2 and Akt mediate multiple growth-factor-induced epithelial-mesenchymal transition in human hepatocellular carcinoma.</a> Journal of Gastroenterology and Hepatology. 27, 566-578 (2012).</li><li>Hanahan, D., Weinberg, R. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+hallmarks+of+cancer.">The hallmarks of cancer.</a> Cell. 100, 57-70 (2000).</li><li>Chambers, A. F., Groom, A. C., MacDonald, I. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Dissemination+and+growth+of+cancer+cells+in+metastatic+sites.">Dissemination and growth of cancer cells in metastatic sites.</a> Nature Reviews Cancer. 2, 563-572 (2002).</li><li>Kim, M. Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Tumor+self-seeding+by+circulating+cancer+cells.">Tumor self-seeding by circulating cancer cells.</a> Cell. 139, 1315-1326 (2009).</li><li>Stolpe, A., Pantel, K., Sleijfer, S., Terstappen, L. W., den Toonder, J. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Circulating+tumor+cell+isolation+and+diagnostics:+toward+routine+clinical+use.">Circulating tumor cell isolation and diagnostics: toward routine clinical use.</a> Cancer Research. 71, 5955-5960 (2011).</li><li>Saad, F., Pantel, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+current+role+of+circulating+tumor+cells+in+the+diagnosis+and+management+of+bone+metastases+in+advanced+prostate+cancer.">The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer.</a> Future Oncology. 8, 321-331 (2012).</li></ol>

The authors declare that they have no competing financial interests.

Bu yazıda yöntemin derinlemesine bir açıklama (Şekil 2) son zamanlarda Ogunwobi ve HCC metastazı ortotopik singeneik fare modeli başarılı kuruluş arkadaşları tarafından rapor edildi verilir 3. Bu prosedür için tümörlerin alım oranı yüksektir. Biz daha önce% 100 3 tümör almak oranı gözlemledik. Ancak, take oranı araştırmacının yetkinlik bağlı değişken olabilir. Eğitim altında yeni bir yüksek lisans öğrencisi tarafından gerçekleştirilen son d...

Hepatocellular carcinoma (HCC) is one of the most lethal cancers, with poor prognosis and low life expectancy. Nearly all cancer-related deaths are due to the metastatic spread of the disease from the originating organ to additional distant organs2-6.HCC progression is a complex process. Therefore, being able to model the tumor microenvironment that is naturally found in metastatic HCC in animal models can prove to be a successful and useful way to reveal relevant mechanisms in humans.7Unfortunately, the mechanisms of cancer metastasis are still largely unclear. Therefore, there is a need to establish animal models that will enable us to elucidate the underlying molecular mechanisms of metastases of cancers such as HCC3,5.
Mouse model systems are a very useful approach for delineating mechanisms and evaluating novel strategies for treatment of metastatic human cancers5,8. The various mouse model systems that presently exist are a testament to efforts of researchers to correctly depict the complexity of the disease5,8,9.
Ogunwobi and colleagues recently used a survival surgical approach to demonstrate establishment of a novel orthotopic syngeneic mouse model for the study of metastasis in HCC3. Their work established a &#8220;patient-like&#8221; mouse model that recapitulates features of aggressive and metastatic HCCs3. They further demonstrated that this mouse model system can be used to study the biology of circulating tumor cells, and that this holds potential for gaining novel insights into the mechanisms of cancer metastasis3.
The aim of this paper is to describe in detail the methodology used in establishing this &#8220;patient-like&#8221; orthotopic syngeneic mouse model of HCC metastasis3. The methodology of how to implant BNL 1ME A.7R.1 mouse HCC cells directly into the liver (the organ of origin) of the inbred wild-type immune competent laboratory mouse strain, BALB/c3 using survival surgery will be described. Unlike other mouse xenograft tumor models where human tumor cells are implanted into immune deficient mice, this system is syngeneic and is, therefore, suitable for studying the role of the immune system in tumor metastasis3,5,8. This approach will likely gain widespread use for studying the mechanisms of metastasis in solid organ cancers.

<table><tbody><tr><td>Micro Dissecting Tweezer&amp;nbsp;</td><td>Roboz</td><td>(RS-5040)</td><td>Tip 0.20 x 0.12 mm</td></tr><tr><td>Graefe Micro Dissecting Forceps, serrated curved tip</td><td>Roboz</td><td>(RS-5111)</td><td>1 X 2 teeth, curved tip width 0.6 mm</td></tr><tr><td>Micro Dissecting Retractor-Agricola (3 by 3 prongs)</td><td>Roboz</td><td>(RS-6501)</td><td>Blunt 3 X 3 prongs, depth 4 mm, spread 25 mm</td></tr><tr><td>Micro Dissecting Retractor-Goldstein (3 by 3 prongs)</td><td>Roboz</td><td>(RS-6503)</td><td>Blunt, 3 X 3 prongs, depth 4 mm, spread 19 mm</td></tr><tr><td>Jameson Caliper (Measures tumors)</td><td>Roboz</td><td>(RS-6466)</td><td>80 mm/3 inch scale, chrome plated&amp;nbsp;</td></tr><tr><td>Micro Dissecting Scissors, large ring sissors, straight and sharp</td><td>Roboz</td><td>(RS-5852)</td><td>23 mm blades, length 4 inches, flat shanks and large rings</td></tr><tr><td>Scalpel with blades, for delicate dissecting procedures</td><td>Roboz</td><td>(RS-9861-36)</td><td></td></tr><tr><td>Scalpel handle&amp;nbsp;</td><td>Roboz</td><td>(RS-9884)</td><td>Solid</td></tr><tr><td>Littauer Stitch Sissors</td><td>Roboz</td><td>(RS-7074)</td><td>Length 4.5 inches</td></tr><tr><td>Brown needle holder, for easy suture tying</td><td>Roboz</td><td>(RS-7960)</td><td>Convex jaw, fine serrations</td></tr><tr><td>Reflex 7MM wound clips with reflex 7 clip applier</td><td>Roboz</td><td>(RS-9262)</td><td>safe, secure alternative method of wound closure</td></tr><tr><td>Instrument tray and lid</td><td>Roboz</td><td>RT-1350S</td><td></td></tr><tr><td>Mini-clipper with detachable blade</td><td>Roboz</td><td>(RS-5903)</td><td></td></tr><tr><td>Germinator 500 (the Germ Terminator) Dry Sterilizer</td><td>Roboz</td><td>Ds-400, Ds-401, DS-501</td><td>For fast decontamination of micro-dissecting instruments.&amp;nbsp;&amp;nbsp; Instruments decontaminate within 15 sec.&amp;nbsp;</td></tr><tr><td>Microinjection needles</td><td>VWR</td><td>BD305125</td><td>25G Needle</td></tr></tbody></table>

a "patient-like" orthotopic syngeneic mouse model of hepatocellular carcinoma metastasis

The majority of cancer-related deaths are caused by the metastasis of the cancer rather than the primary tumor itself. Yet, the underlying mechanisms of cancer metastasis are still unclear. Animal models are essential for elucidating the mechanisms and for evaluating novel strategies for the treatment of metastatic cancers. Here, an in-depth description of a &#8220;patient-like&#8221; orthotopic syngeneic mouse model for exploring the mechanisms of metastasis of solid organ tumors is provided. The survival surgical implantation of BNL 1ME A.7R.1 mouse hepatocellular carcinoma cells directly into the liver (the organ of origin) of the inbred wild-type immune competent laboratory mouse strain, BALB/c is described. The success and reproducibility of this methodology recommends it for widespread use in elucidating the biological mechanisms of solid organ cancer metastasis.

Balb / c fare karaciğerleri 5 x 10 6 BNL 1ME A.7R.1 fare HCC hücrelerinde implante edildi. HCC gelişme Klinik kanıtlar 63 gün ameliyat sonrası gözlemlenebilir oldu. Sonuç olarak, fare insanca kurban edilmiştir. Otopsi Öldürülen farelerin üstünde gerçekleştirilmiştir. Akciğerler ve karaciğer, resekte edilen ve dikkatli bir brüt incelenmesi makroskopik tümörlerin belirlenmesi için gerçekleştirilmiştir. Bir farede, yüzeysel tümör karın duvarı (Şekil 1A) bazı bağ...

Watch this Scientific Journal Video about A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis at JoVE.com

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis

Kanserin metastaz kansere bağlı ölümlerin önemli bir nedenidir. Biz solid organ tümörlerinin metastaz mekanizmaları çalışmak için bir &quot;hasta&quot; gibi ortotopik singenik fare modeli sistemi kurulması için hayatta kalma cerrahi yönteminin derinlemesine bir açıklama sağlar.

Bir &quot;Hasta gibi&quot; Ortotopik singenik Fare Modeli Hepatoselüler karsinomu metastazı

The majority of cancer-related deaths are caused by the metastasis of the cancer rather than the primary tumor itself. Yet, the underlying mechanisms of ...

a-patient-like-orthotopic-syngeneic-mouse-model-hepatocellular

Research

JoVE Journal

Medicine

12.2K Görüntüleme.  Hunter College of the City University of New York.  Kanserin metastaz kansere bağlı ölümlerin önemli bir nedenidir. Biz solid organ tümörlerinin metastaz mekanizmaları çalışmak için bir "hasta" gibi ortotopik singenik fare modeli sistemi kurulması için hayatta kalma cerrahi yönteminin derinlemesine bir açıklama sağlar. 

Video: A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis

Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones

Patients with a limited number of hepatic metastases and slow rates of progression can be successfully treated with local treatment approaches1,2. However, little is known about the heterogeneity of liver metastases, and animal models capable of evaluating the development of individual metastatic colonies are needed. Here, we present an advanced model of hepatic metastases that provides the ability to quantitatively visualize the development of individual tumor clones in the liver and estimate their growth kinetics and colonization efficiency. We generated a panel of monoclonal derivatives of HCT116 human colorectal cancer cells stably labeled with luciferase and tdTomato and possessing different growth properties. With a splenic injection followed by a splenectomy, the majority of these clones are able to generate hepatic metastases, but with different frequencies of colonization and varying growth rates. Using the In Vivo&#160;Imaging System (IVIS), it is possible to visualize and quantify metastasis development with in vivo luminescent and ex vivo fluorescent imaging. In addition, Diffuse Luminescent Imaging Tomography (DLIT) provides a 3D distribution of liver metastases in vivo. Ex vivo fluorescent imaging of harvested livers provides quantitative measurements of individual hepatic metastatic colonies, allowing for the evaluation of the frequency of liver colonization and the growth kinetics of metastases. Since the model is similar to clinically observed liver metastases, it can serve as a modality for detecting genes associated with liver metastasis and for testing potential ablative or adjuvant treatments for liver metastatic disease.

The ability of metastatic clones to colonize distant sites depends on their proliferation capacity and/or their ability to survive in the host microenvironment without significant proliferation. Here, we present an animal model that allows quantitative visualization of both types of liver colonization by metastatic clones.

İleri Hayvan Karaciğer Kolorektal Metastaz Model: Görüntüleme Teknikleri ve Metastatik Klonların Özellikleri

Patients with a limited number of hepatic metastases and slow rates of progression can be successfully treated with local treatment approaches1,2. ...

Kanser Araştırmaları

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Breast cancer is the leading cause of cancer-related mortality in women worldwide. Liver metastasis is involved in upwards of 30% of cases with breast cancer metastasis, and results in poor outcomes with median survival rates of only 4.8 - 15 months. Current rodent models of breast cancer metastasis, including primary tumor cell xenograft and spontaneous tumor models, rarely metastasize to the liver. Intracardiac and intrasplenic injection models do result in liver metastases, however these models can be confounded by concomitant secondary-site metastasis, or by compromised immunity due to removal of the spleen to avoid tumor growth at the injection site. To address the need for improved liver metastasis models, a murine portal vein injection method that delivers tumor cells firstly and directly to the liver was developed. This model delivers tumor cells to the liver without complications of concurrent metastases in other organs or removal of the spleen. The optimized portal vein protocol employs small injection volumes of 5 - 10 &#956;l, &#8805; 32 gauge needles, and hemostatic gauze at the injection site to control for blood loss. The portal vein injection approach in Balb/c female mice using three syngeneic mammary tumor lines of varying metastatic potential was tested; high-metastatic 4T1 cells, moderate-metastatic D2A1 cells, and low-metastatic D2.OR cells. Concentrations of &#8804; 10,000 cells/injection results in a latency of ~ 20 - 40 days for development of liver metastases with the higher metastatic 4T1 and D2A1 lines, and &#62; 55 days for the less aggressive D2.OR line. This model represents an important tool to study breast cancer metastasis to the liver, and may be applicable to other cancers that frequently metastasize to the liver including colorectal and pancreatic adenocarcinomas.

A surgical procedure was developed to deliver mammary tumor cells to the murine liver via portal vein injection. This model permits investigation of late stages of liver metastasis in a fully immune competent host, including tumor cell extravasation, seeding, survival, and metastatic outgrowth in the liver.

Bir Portal Ven Enjeksiyon Modeli Karaciğer Metastazı Meme Kanseri Eğitim için

Breast cancer is the leading cause of cancer-related mortality in women worldwide. Liver metastasis is involved in upwards of 30% of cases with breast ...

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Renal cell carcinoma (RCC) affects &#62; 60,000 people in the United States annually, and ~ 30% of RCC patients have multiple metastases at the time of diagnosis. Metastatic RCC (mRCC) is incurable, with a median survival time of only 18 months. Immune-based interventions (e.g., interferon (IFN) and interleukin (IL)-2) induce durable responses in a fraction of mRCC patients, and multikinase inhibitors (e.g., sunitinib or sorafenib) or anti-VEGF receptor monoclonal antibodies (mAb) are largely palliative, as complete remissions are rare. Such shortcomings in current therapies for mRCC patients provide the rationale for the development of novel treatment protocols. A key component in the preclinical testing of new therapies for mRCC is a suitable animal model. Beneficial features that recapitulate the human condition include a primary renal tumor, renal tumor metastases, and an intact immune system to investigate any therapy-driven immune effector responses and the formation of tumor-induced immunosuppressive factors. This report describes an orthotopic mRCC mouse model that has all of these features. We describe an intrarenal implantation technique using the mouse renal adenocarcinoma cell line Renca, followed by the assessment of tumor growth in the kidney (primary site) and lungs (metastatic site).

Implementation of an orthotopic model of renal cell carcinoma in immunocompetent mice affords the investigator a clinically-relevant system defined by the presence of a primary renal tumor and lung metastases in the same animal. This system can be used to preclinically test a variety of treatments in vivo.

Preklinik Tedaviler Nicel ve Boyuna Değerlendirme A sinjeneik Fare Modeli Yapmış Bir Renal Hücreli Karsinom

Renal cell carcinoma (RCC) affects &#62; 60,000 people in the United States annually, and ~ 30% of RCC patients have multiple metastases at the time of ...

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

The absence of a clinically relevant animal model addressing the typical immune characteristics of hepatocellular cancer (HCC) has significantly impeded elucidation of the underlying mechanisms and development of innovative immunotherapeutic strategies. To develop an ideal animal model recapitulating human HCC, immunocompetent male C57BL/6J mice first receive a carbon tetrachloride (CCl4) injection to induce liver fibrosis, then receive histologically-normal oncogenic hepatocytes from young male SV40 T antigen (TAg)-transgenic mice (MTD2) by intra-splenic (ISPL) inoculation. Androgen generated in recipient male mice at puberty initiates TAg expression under control of a liver-specific promoter. As a result, the transferred hepatocytes become cancer cells and form tumor masses in the setting of liver fibrosis/cirrhosis. This novel model mimics human HCC initiation and progression in the context of liver fibrosis/cirrhosis and reflects the most typical features of human HCC including immune dysfunction.

Here, we describe the development of a clinically relevant murine model of liver cancer recapitulating the typical immune features of hepatocellular cancer (HCC).

Hepatik İnflamasyon ve Fibrozis Ortamında Ortaya Çıkan Hepatosellüler Kanserin Onkojenik Hepatositkaynaklı Ortotopik Fare Modeli

The absence of a clinically relevant animal model addressing the typical immune characteristics of hepatocellular cancer (HCC) has significantly impeded ...

Murine Model of Metastatic Liver Tumors in the Setting of Ischemia Reperfusion Injury

Liver ischemia and reperfusion (I/R) injury, a common clinical challenge, remains an inevitable pathophysiological process that has been shown to induce multiple tissue and organ damage. Despite recent advances and therapeutic approaches, the overall morbidity has remained unsatisfactory especially in patients with underlying parenchymal abnormalities. In the context of aggressive cancer growth and metastasis, surgical I/R is suspected to be the promoter regulating tumor recurrence. This article aims to describe a clinically relevant murine model of liver I/R and colorectal liver metastasis. In doing so, we aim to assist other investigators in establishing and perfecting this model for their routine research practice to better understand the effects of liver I/R on promoting liver metastases.

We describe in detail a clinically relevant colorectal cancer liver metastases (CRLM) tumor model and the influence of liver ischemia reperfusion (I/R) in tumor growth and metastasis. This model can help to better understand the mechanisms underlying surgery-induced promotion of liver metastatic growth.

İskemi Reperfüzyon Hasarı Ayarında Metastatik Karaciğer Tümörlerinin Murine Modeli

Liver ischemia and reperfusion (I/R) injury, a common clinical challenge, remains an inevitable pathophysiological process that has been shown to induce ...

Generation of a Liver Orthotopic Human Uveal Melanoma Xenograft Platform in Immunodeficient Mice

In recent decades, subcutaneously implanted patient-derived xenograft tumors or cultured human cell lines have been increasingly recognized as more representative models to study human cancers in immunodeficient mice than traditional established human cell lines in vitro. Recently, orthotopically implanted patient-derived tumor xenograft (PDX) models in mice have been developed to better replicate features of patient tumors. A liver orthotopic xenograft mouse model is expected to be a useful cancer research platform, providing insights into tumor biology and drug therapy. However, liver orthotopic tumor implantation is generally complicated. Here we describe our protocols for the orthotopic implantation of patient-derived liver-metastatic uveal melanoma tumors. We cultured human liver metastatic uveal melanoma cell lines into immunodeficient mice. The protocols can result in consistently high technical success rates using either a surgical orthotopic implantation technique with chunks of patient-derived uveal melanoma tumor or a needle injection technique with cultured human cell line. We also describe protocols for CT scanning to detect interior liver tumors and for re-implantation techniques using cryopreserved tumors to achieve re-engraftment. Together, these protocols provide a better platform for liver orthotopic tumor mouse models of liver metastatic uveal melanoma in translational research.

Orthotopic human liver metastatic uveal melanoma xenograft mouse models were created using surgical orthotopic implantation techniques with patient-derived tumor chunk and needle injection techniques with cultured human uveal melanoma cell lines.

İmmünficient Farelerde Karaciğer Ortotopik İnsan Uveal Melanom Xenograft Platformu Üretimi

In recent decades, subcutaneously implanted patient-derived xenograft tumors or cultured human cell lines have been increasingly recognized as more ...

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

In vivo experimental models of hepatocellular carcinoma (HCC) that recapitulate the human disease provide a valuable platform for research into disease pathophysiology and for the preclinical evaluation of novel therapies. We present a variety of methods to generate subcutaneous or orthotopic human HCC xenografts in immunodeficient mice that could be utilized in a variety of research applications. With a focus on the use of primary tumor tissue from patients undergoing surgical resection as a starting point, we describe the preparation of cell suspensions or tumor fragments for xenografting. We describe specific techniques to xenograft these tissues i) subcutaneously; or ii) intrahepatically, either by direct implantation of tumor cells or fragments into the liver, or indirectly by injection of cells into the mouse spleen. We also describe the use of partial resection of the native mouse liver at the time of xenografting as a strategy to induce a state of active liver regeneration in the recipient mouse that may facilitate the intrahepatic engraftment of primary human tumor cells. The expected results of these techniques are illustrated. The protocols described have been validated using primary human HCC samples and xenografts, which typically perform less robustly than the well-established human HCC cell lines that are widely used and frequently cited in the literature. In comparison with cell lines, we discuss factors which may contribute to the relatively low chance of primary HCC engraftment in xenotransplantation models and comment on technical issues that may influence the kinetics of xenograft growth. We also suggest methods that should be applied to ensure that xenografts obtained accurately resemble parent HCC tissues.

Human tumor xenografts in immunodeficient mice are valuable tools to study cancer biology. Specific protocols to generate subcutaneous and intrahepatic xenografts from human hepatocellular carcinoma cells or tumor fragments are described. Liver regeneration induced by partial hepatectomy in recipient mice is presented as a strategy to facilitate intrahepatic engraftment.

Bağışıklık yetersizliği olan farelere subkutan olarak ve intrahepatik insan hepatoselüler karsinoma ksenograftlarının Üretimi

In  vivo experimental models of hepatocellular carcinoma (HCC) that recapitulate  the human disease provide a valuable platform for research into disease  ...

Tıp

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma

Preclinical experimental models of hepatocellular carcinoma (HCC) that recapitulate human disease represent an important tool to study tumorigenesis and evaluate novel therapeutic approaches. Non-invasive whole-body imaging using positron emission tomography (PET) provides critical insights into the in vivo characteristics of tissues at the molecular level in real-time. We present here a protocol for orthotopic HCC xenograft creation with and without hepatic artery ligation (HAL) to induce tumor hypoxia and the assessment of their tumor metabolism in vivo using [18F]Fluoromisonidazole ([18F]FMISO) and [18F]Fluorodeoxyglucose ([18F]FDG) PET/magnetic resonance (MR) imaging. Tumor hypoxia could be readily visualized using the hypoxia marker [18F]FMISO, and it was found that the [18F]FMISO uptake was higher in HCC mice that underwent HAL than in the non-HAL group, whereas [18F]FDG could not distinguish tumor hypoxia between the two groups. HAL tumors also displayed a higher level of hypoxia-inducible factor (HIF)-1&#945; expression in response to hypoxia. Quantification of HAL tumors showed a 2.3-fold increase in [18F]FMISO uptake based on the standardized value uptake (SUV) approach.

Here, we present a protocol to create orthotopic hepatocellular carcinoma xenografts with and without hepatic artery ligation and perform non-invasive positron emission tomography (PET) imaging of tumor hypoxia using [18F]Fluoromisonidazole ([18F]FMISO) and [18F]Fluorodeoxyglucose ([18F]FDG).

Hepatosellüler Karsinomun Ortotopik Fare Modelinde Non-İnvaziv PET/MR Görüntüleme

Preclinical experimental models of hepatocellular carcinoma (HCC) that recapitulate human disease represent an important tool to study tumorigenesis and ...

A Preclinical Murine Model of Hepatic Metastases

Numerous murine models have been developed to study human cancers and advance the understanding of cancer treatment and development. Here, a preclinical, murine pancreatic tumor model of hepatic metastases via a hemispleen injection of syngeneic murine pancreatic tumor cells is described. This model mimics many of the clinical conditions in patients with metastatic disease to the liver. Mice consistently develop metastases in the liver allowing for investigation of the metastatic process, experimental therapy testing, and tumor immunology research.

A preclinical, murine model of hepatic metastases performed via a hemispleen injection technique.

Karaciğer metastazları Klinik öncesi fare modeli

Numerous murine models have been developed to study human cancers and advance the understanding of cancer treatment and development. Here, a preclinical, ...

<meta charset="utf8"></head><body>Karaciğer Rejenerasyon Çalışması için Hasta Kaynaklı Hepatokarsinom Hücre Organoidleri

A Hepatocellular Cancer Patient&#45;Derived Organoid Xenograft Model to Investigate Impact of Liver Regeneration on Tumor Growth

Recurrence poses a notable challenge after hepatocellular carcinoma (HCC) treatment, impacting more than 70% of patients who undergo surgical resection. Recurrence stems from undetected micro-metastasis or de novo cancer, potentially triggered by postsurgical liver regeneration. Prior research employed HCC cell lines in orthotopic models to study the impact of liver regeneration, but their limited validity prompted the need for a more representative model. Here, we introduce a novel approach utilizing patient-derived HCC organoids to investigate the influence of liver regeneration on HCC.
Patient tumor tissues are processed to create tumor organoids, embedded in a three-dimensional basement membrane matrix, and cultured in a liver-specific medium. One million organoids are injected into the right superior lobe (RSL) of immunodeficient mice, confirming macroscopic tumor growth through sonography. The intervention group undergoes resection of the left lateral lobe (LLL) (30% of total liver volume) or additionally, the middle lobe (ML) (65% of total liver volume) to induce liver regeneration within the tumor site. The control group experiences re-laparotomy without liver tissue resection. After 2 weeks, both groups undergo tumor and normal tissue explantation.
In conclusion, this patient-derived HCC organoid model offers a robust platform to investigate the impact of liver regeneration post-cancer resection. Its multi-cellular composition, genetic diversity, and prolonged culture capabilities make it an invaluable tool for studying HCC recurrence mechanisms and potential interventions.

<meta charset="utf8"></head><body>Karaciğer Rejenerasyonunun Tümör Büyümesi Üzerindeki Etkisini Araştırmak İçin Hepatosellüler Kanser Hastasından Elde Edilen Bir Organoid Ksenogreft Modeli

Organoids generated from patient tumors are orthotopically injected into the mouse liver. The resection of non-tumorous liver tissue leads to a regenerative environment in the liver tissue where the tumor is located.

Karaciğer Rejenerasyonunun Tümör Büyümesi Üzerindeki Etkisini Araştırmak İçin Hepatosellüler Kanser Hastasından Elde Edilen Bir Organoid Ksenogreft Modeli

Recurrence poses a notable challenge after hepatocellular carcinoma (HCC) treatment, impacting more than 70% of patients who undergo surgical resection. ...

Bir "Hasta gibi" Ortotopik singenik Fare Modeli Hepatoselüler karsinomu metastazı

Özet

Daha Fazla Video Keşfet

Bu videodaki bölümler